MOTS-c is a small peptide that your mitochondria make on their own. In a 2021 mouse study, treating mice with it improved their running ability at every age tested. In people, researchers have only measured that MOTS-c levels rise after exercise. No one has shown that taking MOTS-c helps a person. It is not an FDA-approved drug.
That is the short version. The rest of this article covers what the study did, what it did not test, and why the gap between mice and people matters.
What is MOTS-c?
Most of your genes sit in the nucleus of each cell. Mitochondria carry a small set of their own. One of those genes codes for MOTS-c. The name stands for mitochondrial open reading frame of the 12S rRNA type-c. It is a short chain of amino acids, which makes it a peptide.
Researchers call it a mitochondrial-derived peptide. Cells appear to use it as a signal. It can act inside the cell that made it. It also circulates in blood.
I covered the broader peptide landscape in our overview of growth hormone secretagogues. MOTS-c is a different kind of peptide. It does not act on the pituitary gland. The research interest here is metabolism and exercise.
What did the 2021 mouse study test?
The key paper is Reynolds and colleagues, published in Nature Communications in 2021. The team studied mice at three ages: young, middle-aged and old. Mice were 2, 12 and 22 months old at the start. Another group began treatment very late in life, at about 23.5 months.
Here is what they reported.
Old mice ran about twice as long and 2.16 times as far as untreated mice. In the old group, 17 percent of treated mice reached the final stage of the running test. None of the untreated old mice did.
Young mice on a high-fat diet also did better. In the higher-dose group, all of them reached the final sprint stage. In the lower-dose and control groups, 16.6 percent did.
Late-life treatment improved grip strength in old mice. The authors reported a P value of 0.000078 for that result. Fat mass fell significantly in the old mice. Age-related loss of lean mass was modestly reduced.
The team also looked at what was happening in muscle. Their metabolite and gene activity data pointed to changes in glycolysis, amino acid metabolism and AMPK signaling. AMPK is a cell energy sensor. Exercise turns it on.
What did the mouse study not show?
This part matters most. The same paper lists several limits.
Young mice on a normal diet did not gain grip strength. The benefit was not the same in every group.
The authors reported a trend toward longer life in treated mice, but it was not statistically significant overall (P = 0.23). They wrote that larger cohorts will be needed to confirm the broader significance of MOTS-c treatment on overall longevity.
They also noted that individual-to-individual variability was high. They called the work a proof-of-principle study. Changes in very old mice at 30 months were marginal.
Mice are not small people. A mouse lives about two years. Their muscle, hormones and exercise habits differ from ours. A result in mice often fails to carry over to humans. I will not give any mouse dose or method here. Those numbers do not translate to people, and no safe human amount has been set.
What do we know about MOTS-c in people?
Very little. The Nature Communications paper included one small human measurement. Researchers studied 10 sedentary young men, with an average age of 24.5 years. They took muscle samples and blood before, during and after exercise.
Muscle MOTS-c rose 11.9-fold after exercise (P = 0.0098). Blood levels rose 1.6-fold during exercise and 1.5-fold after.
So exercise raises your own MOTS-c. That is a measurement, not a treatment trial. It did not test whether giving extra MOTS-c helps anyone. It did not include women, older adults or people with health conditions.
Does this mean exercise already does the job?
Your body makes MOTS-c when you move. That finding fits what we already know. Resistance training and aerobic work improve metabolic health, muscle and mobility with decades of human evidence behind them.
For women in perimenopause and menopause, muscle and strength matter. Grip strength and chair stands predicted survival in one large study. A smaller weekly dose of lifting can protect muscle. Steady aerobic work supports the brain.
The mouse data is interesting. The human plan is simpler. Lift, walk, sleep and get your bloodwork checked.
How should you read an animal study?
Animal studies are the first step in a long chain. They show that an idea is worth testing. They do not show that it works in people.
Here is the path a compound takes. Researchers test it in cells. They test it in animals. Then they test safety in a small group of people. Then they test whether it works in a larger group, with a control arm. Many ideas fail along the way.
MOTS-c sits near the start of that path. The 2021 paper is a careful, well-reported study. It is also a proof of principle in mice, and the authors say so.
When you see a headline about a peptide, ask four questions. Who was studied? Was it a mouse, a cell or a person? How many were in the group? What did the authors say they could not conclude?
For MOTS-c, the answers are mice, mostly, small groups and no human treatment data.
What should you ask a clinician about peptides?
If you are curious about any peptide, bring it to a licensed prescriber. Good questions include these. Is there human evidence for my goal? What is the FDA status today? What labs or health history would change the answer? What would we do first without a peptide?
A good clinician will not rush you. They will tell you where the evidence is thin. They will also tell you what has strong support for your goal, and that list is often exercise, protein, sleep and medical care for any underlying condition.
What is the FDA status of MOTS-c?
MOTS-c is not an FDA-approved drug. It is not on the FDA list of bulk substances that pharmacies may compound under section 503A. A law firm client alert from July 2026 says FDA placed MOTS-c in Category 2 in 2023.
In July 2026, FDA's Pharmacy Compounding Advisory Committee met to consider MOTS-c and other peptides. That vote is advisory. FDA decides whether to follow it, and any change would go through formal rulemaking. That process can take a long time.
Rules in this area are changing. Check FDA's current list before you rely on anything you read, including here.
Products sold online as research chemicals are not the same as medicines made under a prescription and pharmacy oversight. I do not discuss where to buy peptides. I do not give dosing or protocols for them.
Frequently asked questions
Is MOTS-c safe?
We do not know. Human safety data from treatment trials is not available in the paper I reviewed. I cannot call it safe or unsafe for people.
Can MOTS-c help with weight loss?
In the mouse study, fat mass fell in old mice. The paper also noted that mice on a normal diet and young mice did not show every benefit. No human trial in this article tested weight loss. If you want to talk about weight, our medically supervised weight loss medication pathway is the right place to start.
Is MOTS-c the same as a growth hormone secretagogue?
No. Sermorelin, CJC-1295, ipamorelin and tesamorelin act on the growth hormone axis. I wrote about that class here and here. MOTS-c comes from mitochondria and works through different pathways.
Will exercise raise my MOTS-c?
In the small study above, it did in young men. The same measurement has not been shown for midlife women in this paper.
Should I take MOTS-c?
That is a conversation for a licensed prescriber who knows your history. This article does not recommend it.
What this means in Dartmouth and the SouthCoast
Many women I work with in Dartmouth, New Bedford, Westport and Fairhaven ask about peptides they see online. I understand the curiosity. My advice is to start where the evidence is strongest. Build strength. Protect sleep. Check iron, thyroid and hormones. Then ask what else makes sense.
I build the program and coach the training. Our collaborating NP or MD prescribes and orders.
If you want a plan built around your labs and goals, a genomic panel can help guide it. If you are in the menopause transition, see our approach here.
Sources
- Zheng, Wei, Wang. Review of MOTS-c. Frontiers in Endocrinology. 2023.
Disclaimer
This article is for informational and educational purposes only. It is not medical advice, diagnosis or treatment. Most of the research described here was done in animals. Talk with a licensed clinician before you make health decisions. Regulatory status can change. Check FDA's current list.